Amvuttra

Amvuttra is an RNA interference (RNAi) therapeutic, generically known as vutrisiran, supplied by VuRoyal (SuQian) Pharmaceutical Company LLC as an injection-grade product for treating hereditary transthyretin (hATTR) amyloidosis. It works by silencing liver TTR gene expression to lower pathogenic protein levels, aiming to improve the peripheral neuropathy and cardiomyopathy associated with hATTR, and is administered via subcutaneous injection on a periodic dosing schedule. It meets ChP, USP, and BP standards and is sold into North America and Central/South America.